![](/imgs/covers/cr_cover.jpg)
|
Journal of Cancer Research and Therapeutics
Medknow Publications on behalf of the Association of Radiation Oncologists of India (AROI)
ISSN: 0973-1482 EISSN: 0973-1482
Vol. 1, No. 1, 2005, pp. 38-40
|
Bioline Code: cr05009
Full paper language: English
Document type: Research Article
Document available free of charge
|
|
Journal of Cancer Research and Therapeutics, Vol. 1, No. 1, 2005, pp. 38-40
en |
A phase I trial of tocoferol monoglucoside in patients undergoing hemi-body radiation
Huilgol N.G., Nair C.K.K., Merhotra P., Kagiya V.T.
Abstract
Purpose
: To evaluate Tocoferol monoglucoside (TMG), a water soluble vit. E. in a phase I trial, as a radiation protector in those undergoing hemi-body radiation for disseminated disease.
Materials and Methods: Patients scheduled to receive modified hemi-body radiation were accrued for the study. Patients not only had disseminated skeletal disease but, were heavily pretreated Seven patients were accrued for the study. Patients received 1 and 2 gms of TMG. 30-40 minutes before hemibody radiation. A dose of 600 cGy was delivered on telecobalt equipment at mid plane. Immediate Toxicities were evaluated as well as response to pain.
Results: All the seven patients underwent radiation uneventfully. There was no drug related toxicity. Pain relief was adequate.
Conclusion: Tocoferol monoglucoside an effective antioxidant with no significant acute toxicity, when administered in a dose of 1 or 2 gms per oral route. TMG being water-soluble can have global antioxidant and radio protective effects. This needs further clinical evaluation.
Keywords
Tocoferol Monoglucoside, Hemidbody Radiation, Radiation Protector, Anti Oxidant
|
|
© Copyright 2005 Journal of Cancer Research and Therapeutics. Alternative site location: http://www.cancerjournal.net/
|
|